Alpha 2.0
Login Register
» Authors » William Travis

William Travis

Explore the profile of William Travis including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 44
Citations 2338
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
General Surgery
Top 10 Co-Authors
Andrew G Nicholson
Mark G Kris
James Huang
Andreas Rimner
Anja C Roden
Natasha Rekhtman
Marc Ladanyi
Mary Beth Beasley
Ming-Sound Tsao
Fred R Hirsch
Published In
J Thorac Oncol
Chest
Genes Chromosomes Cancer
Lung Cancer
Eur J Cardiothorac Surg
Affiliations
Soon will be listed here.
Recent Articles
1.
Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee
Chou T, Dacic S, Wistuba I, Beasley M, Berezowska S, Chang Y, et al.
J Thorac Oncol . 2024 Nov; 20(3):311-330. PMID: 39579981
Introduction: With the implementation of low-dose computed tomography screening, multiple pulmonary tumor nodules are diagnosed with increasing frequency and the selection of surgical treatments versus systemic therapies has become challenging...
2.
Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer
Liu S, Erazo T, Jee J, Arfe A, Gupta A, Pike L, et al.
Eur J Cancer . 2024 Aug; 210:114257. PMID: 39151324
Introduction: No definitive answers currently exist regarding optimal first-line therapy for HER2-mutant NSCLC. Access to rapid tissue sequencing is a major barrier to precision drug development in the first-line setting....
3.
International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy
Dacic S, Travis W, Redman M, Saqi A, Cooper W, Borczuk A, et al.
J Thorac Oncol . 2023 Sep; 18(10):1290-1302. PMID: 37702631
Introduction: Pathologic response has been proposed as an early clinical trial end point of survival after neoadjuvant treatment in clinical trials of NSCLC. The International Association for the Study of...
4.
Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library
Offin M, Sauter J, Tischfield S, Egger J, Chavan S, Shah N, et al.
Genome Med . 2022 Nov; 14(1):127. PMID: 36380343
Background: Diffuse pleural mesothelioma (DPM) is an aggressive malignancy that, despite recent treatment advances, has unacceptably poor outcomes. Therapeutic research in DPM is inhibited by a paucity of preclinical models...
5.
The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities
Osarogiagbon R, Rami-Porta R, Tsao M, Montuenga L, Nishimura K, Giroux D, et al.
J Thorac Oncol . 2021 Mar; 16(6):897-901. PMID: 33771657
No abstract available.
6.
The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC
Mino-Kenudson M, Le Stang N, Daigneault J, Nicholson A, Cooper W, Roden A, et al.
J Thorac Oncol . 2021 Mar; 16(4):686-696. PMID: 33662578
Introduction: Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) is required to determine the eligibility for pembrolizumab monotherapy in advanced NSCLC worldwide and for several other indications depending on the country. Four...
7.
Rapid EGFR Mutation Detection Using the Idylla Platform: Single-Institution Experience of 1200 Cases Analyzed by an In-House Developed Pipeline and Comparison with Concurrent Next-Generation Sequencing Results
Momeni-Boroujeni A, Salazar P, Zheng T, Mensah N, Rijo I, Dogan S, et al.
J Mol Diagn . 2020 Dec; 23(3):310-322. PMID: 33346146
Mutations in the epidermal growth factor receptor (EGFR) are the most common targetable alterations in lung adenocarcinoma. To facilitate rapid testing, the Idylla EGFR assay was incorporated as a screening...
8.
Molecular differences across invasive lung adenocarcinoma morphological subgroups
Ci B, Yang D, Cai L, Yang L, Girard L, Fujimoto J, et al.
Transl Lung Cancer Res . 2020 Sep; 9(4):1029-1040. PMID: 32953482
Background: Lung adenocarcinomas (ADCs) show heterogeneous morphological patterns that are classified into five subgroups: lepidic predominant, papillary predominant, acinar predominant, micropapillary predominant and solid predominant. The morphological classification of ADCs...
9.
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
Sholl L, Hirsch F, Hwang D, Botling J, Lopez-Rios F, Bubendorf L, et al.
J Thorac Oncol . 2020 Jun; 15(9):1409-1424. PMID: 32522712
Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients with NSCLC and have led to unprecedented improvements in response rates and survival in a subset of patients with...
10.
State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach
Levy E, Fiel M, Hamilton S, Kleiner D, McCall S, Schirmacher P, et al.
J Clin Oncol . 2020 Mar; 38(14):1633-1640. PMID: 32134701
Purpose: National Cancer Institute (NCI)-sponsored clinical trial network studies frequently require biopsy specimens for pharmacodynamic and molecular biomarker analyses, including paired pre- and post-treatment samples. The purpose of this meeting...